Protagonist Therapeutics (PTGX) Cash & Equivalents (2015 - 2026)

Protagonist Therapeutics has disclosed Cash & Equivalents across 12 years of filings, most recently posting $193.7 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $193.7 million, up 38.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $193.7 million (up 38.71% YoY), and the FY2025 annual result was $128.4 million, up 32.02% from the prior year.
• Cash & Equivalents came in at $193.7 million for Q1 2026 at Protagonist Therapeutics, up from $128.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $355.6 million in Q2 2024 to a low of $97.2 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $139.7 million (2025), against an average of $163.4 million.
• Across the five-year window, Cash & Equivalents surged 95.77% in 2023 and sank 52.61% in 2025, its largest moves.
• Protagonist Therapeutics' Cash & Equivalents stood at $125.7 million in 2022, then soared by 48.5% to $186.7 million in 2023, then slumped by 47.92% to $97.2 million in 2024, then surged by 32.02% to $128.4 million in 2025, then soared by 50.88% to $193.7 million in 2026.
• The last three Cash & Equivalents figures came in at $193.7 million (Q1 2026), $128.4 million (Q4 2025), and $113.7 million (Q3 2025), per Business Quant data.